pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
September 27 2016 - 7:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the
development of sustained release drug delivery products for
treating eye diseases, today announced the appointment of Jay S.
Duker, M.D, to the Company’s Board of Directors. Dr. Duker is
the Director of the New England Eye Center and Professor and
Chairman of Ophthalmology at the Tufts Medical Center and the Tufts
University School of Medicine.
“Dr. Jay Duker is a recognized international
expert in the treatment of diseases of the back of the eye,” said
David J. Mazzo, Ph.D., Chairman of pSivida’s Board of Directors.
“Dr. Duker’s unique combination of academic, research and clinical
experience with ophthalmic disease will be a significant asset to
pSivida. His contributions will be invaluable and I, along
with the other Directors, look forward to working with him to
advance our Company to the next level of success.”
As chairman of ophthalmology for Tufts Medical
Center, Dr. Duker is responsible for managing the hospital's
clinical ophthalmology practice. His role as chairman of
ophthalmology for Tufts University School of Medicine encompasses
leading the academic mission of the school, educating medical
students, residents, fellows and practicing eye-care providers in
ophthalmology and conducting ophthalmic research. As the Director
of the New England Eye Center, he leads an academic,
multi-specialty eye care group with 35 ophthalmologists and nearly
200 employees.
“Dr. Duker’s well-earned reputation among the
ophthalmologist community combined with his scientific experience
in eye diseases and corporate success bring a unique blend of
science and business acumen to the pSivida board,” commented Nancy
Lurker, President and Chief Executive Officer. “His addition
further strengthens the Board’s capabilities and I’m excited to
work alongside him to execute our business plan.”
In his clinical practice, Dr. Duker treats
diseases of the posterior segment of the eye including age-related
macular degeneration (AMD), diabetic retinopathy, posterior segment
uveitis and retinal vascular diseases as well as rare retinal
disorders. His principal research interests include retinal
vascular disease, drug delivery to the eye, posterior uveitis and
novel imaging techniques for the posterior segment. He has
published nearly 200 peer-reviewed journal articles and authored
four books on ophthalmology including a best-selling
textbook. Dr. Duker serves on the editorial board of three
ophthalmic journals. He is a graduate of Harvard University and
Jefferson Medical College.
Dr. Duker is also a director of Eleven
Biotherapeutics, a biopharmaceutical company discovering and
developing protein therapeutics to treat diseases of the
eye, and a co-founder and Director of Hemera Biosciences, a
privately held company seeking to develop anti-complement gene
based therapies for the treatment of dry and wet age related
macular degeneration.
About pSivida Corp. pSivida
Corp. (www.psivida.com), headquartered in Watertown, MA, is a
leader in the development of sustained release, drug delivery
products for treating eye diseases. pSivida has developed three of
only four FDA-approved sustained-release treatments for
back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert
for diabetic macular edema, licensed to Alimera Sciences, is
currently sold in the U.S. and three EU countries. Retisert®, an
implant for posterior uveitis, is licensed to and sold by Bausch
& Lomb. pSivida’s lead product candidate, Medidur™, a
micro-insert for posterior uveitis being independently developed,
is currently in pivotal Phase 3 clinical trials. pSivida’s
pre-clinical development program is focused on using its core
platform technologies Durasert™ and Tethadur™ to deliver drugs and
biologics to treat wet and dry age-related macular degeneration,
glaucoma, osteoarthritis and other diseases. To learn more about
pSivida please visit www.psivida.com and connect on Twitter,
LinkedIn, Facebook and Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made
in this release are forward-looking, and are inherently subject to
risks, uncertainties and potentially inaccurate assumptions. All
statements that address activities, events or developments that we
intend, expect or believe may occur in the future are
forward-looking statements. Some of the factors that could cause
actual results to differ materially from the anticipated results or
other expectations expressed, anticipated or implied in our
forward-looking statements include uncertainties with respect to:
our ability to obtain needed capital; our ability to achieve
profitable operations; potential declines in Retisert royalties;
fluctuations in our operating results; further impairment of our
intangible assets; our ability to obtain marketing approvals for
and successfully commercialize Medidur for posterior segment
uveitis; performance by CROs, vendors and investigators; timing of
filing marketing approval applications for Medidur; acceptability
of data to be filed in support of Medidur marketing applications;
maintenance of orphan designation for Medidur, potential off-label
sales of ILUVIEN for posterior segment uveitis; successful
commercialization of, and receipt of revenues from, ILUVIEN for
DME; Alimera’s ability to continue as a going concern; the effect
of pricing and reimbursement decisions on sales of ILUVIEN for DME;
consequences of fluocinolone acetonide side effects; outcome of
dispute with Alimera on commercialization expenses; any exercise by
Pfizer of its option with respect to the latanoprost product; our
ability to develop Tethadur to successfully deliver large biologic
molecules and develop products using it; efficacy and future
development of severe OA implant by us; our ability to successfully
develop product candidates, initiate and complete clinical trials
and receive regulatory approvals; our ability to market and sell
products; the success of current and future license agreements;
termination or breach of current license agreements; effects of
competition and other developments affecting sales of products;
market acceptance of products; effects of guidelines,
recommendations and studies; protection of intellectual property
and avoiding intellectual property infringement; retention of key
personnel; product liability; industry consolidation; compliance
with environmental laws; manufacturing risks; risks and costs of
international business operations; effects of potential U.K. exit
from the EU; legislative or regulatory changes; volatility of stock
price; possible dilution; absence of dividends; and other factors
described in our filings with the SEC. You should read and
interpret any forward-looking statements in light of these risks.
Should known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or
projected in the forward-looking statements. You should bear this
in mind as you consider any forward-looking statements. Our
forward-looking statements speak only as of the dates on which they
are made. We do not undertake any obligation to publicly update or
revise our forward-looking statements even if experience or future
changes makes it clear that any projected results expressed or
implied in such statements will not be realized.
Contact:
EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 415.652.9100
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024